Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis

Arthritis and Rheumatology

Volumn 66, Issue 2, 2014, Pages 264-272

  Del Rincón, Inmaculada ^a   Battafarano, Daniel F ^b   Restrepo, Jose F ^a   Erikson, John M ^a   Escalante, Agustín ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; PREDNISONE;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEMOGRAPHY; DOSE RESPONSE; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SOCIAL STATUS; VITAL STATISTICS;

ADULT; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; INCIDENCE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PREDNISONE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84896276286     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38210     Document Type: Article

References (33)

1. Kirwan JR, and the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333: 142-6.
2. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
3. [published erratum appears in Lancet 1998;351:220]
4. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007:CD006356.
5. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96: 115-23.
6. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006;55: 420-6.
7. Leigh JP, Fries JF. Mortality predictors among 263 patients with rheumatoid arthritis. J Rheumatol 1991;18: 1307-12.
8. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37: 481-94.
9. Sihvonen S, Korpela M, Mustonen J, Huhtala H, Karstila K, Pasternack A. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids: a population-based cohort study. J Rheumatol 2006;33: 1740-6.
10. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141: 764-70.
11. Davis JM III, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007;56: 820-30.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31: 315-24.
13. Parkerson GR Jr, Broadhead WE, Tse CK. The Duke Severity of Illness Checklist (DUSOI) for measurement of severity and comorbidity. J Clin Epidemiol 1993;46: 379-93.
14. Navarro-Cano G, del Rincon I, Pogosian S, Roldan JF, Escalante A. Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity. Arthritis Rheum 2003;48: 2425-33.
15. Orces CH, del Rincon I, Abel MP, Escalante A. The number of deformed joints as a surrogate measure of damage in rheumatoid arthritis. Arthritis Rheum 2002;47: 67-72.
16. Nam CB, Powers MG. The socioeconomic approach to status measurement with a guide to occupational and socioeconomic status scores. Houston: Cap & Gown Press; 1983.
17. Del Rincon I, O'Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004;50: 3813-22.
18. published erratum appears in Arthritis Rheum 2005;52:678
19. Cox DR. Some simple approximate tests for Poisson variables. Biometrika 1953;40: 354-60.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
21. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972;34: 187-220.
22. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79: 516-24.
23. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81: 515-26.
24. Hosmer DW, Lemeshow S. Applied survival analysis: regression modeling of time to event data. New York: John Wiley & Sons; 1999. p. 196-240.
25. Allebeck P, Rodvall Y, Allander E. Mortality in rheumatoid arthritis, particularly as regards drug use. Scand J Rheumatol 1985;14: 102-8.
26. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986;29: 706-14.
27. Corbett M, Dalton S, Young A, Silman A, Shipley M. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheumatol 1993;32: 717-23.
28. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997;24: 445-51.
29. Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates and outcomes. J Rheumatol 2007;34: 696-705.
30. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66: 1560-7.
31. Pincus T, Sokka T, Stein CM. Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful? Ann Intern Med 2002;136: 76-8.
32. Boers M. Studying the benefit/risk ratio of glucocorticoids in rheumatoid arthritis. J Rheumatol 2007;34: 661-3.
33. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17: 2265-81.